The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1591
ISSUE1591
February 10, 2020
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
February 10, 2020 (Issue: 1591)
The FDA has approved a progestin-only oral
contraceptive ("minipill") containing drospirenone
(Slynd – Exeltis). All other progestin-only oral
contraceptives available in the US contain
norethindrone (Camila, and others). Progestin-only...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.